Generic Name and Formulations:
Nabilone 1mg; caps.
Bausch Health Companies Inc.
Indications for CESAMET:
Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have not responded adequately to other antiemetics.
1–2mg twice daily; max 6mg/day in 3 divided doses. Give 1st dose 1–3 hours before chemotherapy is administered; use lower starting dose and increase if necessary. May give 1–2mg the night before chemo. Continue 2–3 doses/day during chemotherapy course, if needed, may continue 48 hours after each chemo cycle.
<18yrs: not recommended.
Hypertension. Heart disease. History of psychiatric disorders (eg, bipolar disorder, depression, schizophrenia) or substance abuse. Write ℞ for limited quantity (ie, enough for one chemotherapy course). Keep patient under responsible adult supervision (esp. when dose is adjusted). Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates CNS depression with benzodiazepines, barbiturates, alcohol, other CNS depressants and other psychoactive substances (avoid). May affect, or be affected by, other drugs that undergo first-pass hepatic metabolism or that are highly protein bound (eg, sympathomimetics, anticholinergics, tricyclic antidepressants). Cross-tolerance and mutual potentiation with opioids. Naltrexone: see literature.
Drowsiness, vertigo, dry mouth, euphoria/dysphoria, ataxia, headache, tachycardia, hypotension, concentration difficulties, sleep disturbance, other psychiatric reactions (may persist for several days after dosing), changes in appetite.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds